Teva Pharmaceutical Industries Ltd. (TEVA)
|Net Income (ttm)||-1.29B|
|Day's Range||8.61 - 8.72|
|52-Week Range||6.78 - 11.34|
|Price Target||0.03 (-99.7%)|
|Earnings Date||Nov 3, 2022|
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it f... [Read more]
Financial PerformanceFinancial Statements
According to 8 analysts, the average rating for TEVA stock is "Buy." The 12-month stock price forecast is 0.03, which is a decrease of -99.65% from the latest price.
These three leading companies are ripe for the picking and may never be this cheap again.
Teva Pharmaceutical (TEVA) appoints Richard Francis as the company's new president and chief executive officer, effective from Jan 1, 2023.
TEL AVIV, Israel & PARSIPPANY, N.J.--( BUSINESS WIRE )--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the company has finalize...
Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat illnesses such as rheum...
Teva Pharmaceuticals (NYSE: TEVA ) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO. Francis will take over as the president and CEO of Teva Pharmac...
Teva Pharmaceutical Industries Ltd. TEVA, +0.93% on Monday said its current CEO Kåre Schultz will retire on Dec. 31.
TEL AVIV, Israel--( BUSINESS WIRE )--Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE and TASE: TEVA), today announced that the Company's Board of Directors has appointed Richard Fran...
Three-Stock Lunch: AMD, HAS & TEVA
Craig Johnson, chief market technician at Piper Sandler, joins 'Power Lunch' to offer his picks for today's three-stock lunch, looking at the technicals of Advanced Micro, Hasbro and Teva Pharmaceuticals.
Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform
PARSIPPANY, N.J.--( BUSINESS WIRE )--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new collaboration with Rimidi, a leading clini...
Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform
PARSIPPANY, N.J.--( BUSINESS WIRE )--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new collaboration with HealthSnap, a leading f...
Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury dec...
You don't need a large pile of cash to begin building wealth on Wall Street.
Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, As...
TEL AVIV, Israel & PARSIPPANY, N.J.
A degree of uncertainty about the company's leadership compounded some rather discouraging recent developments.
TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
There were two major developments with the company, both of which involved piles of money.
Mr. Schultz said he won't renew his contract that expires in November 2023.
The Israeli company will shell out as much as $4.2 billion nationwide as part of a tentative deal.
New York Attorney General Letitia James secures $523 million from Teva Pharmaceuticals for role in opioid crisis
The New York Attorney General's office announced it has secured $523 million from Teva Pharmaceuticals and affiliates for its role in the opioid crisis, effectively marking the end of the state's litiga...
Teva Pharmaceutical Industries Ltd will pay up to $523 million to New York State as part of a nationwide settlement of lawsuits alleging the company helped fuel the U.S. opioid epidemic.
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd.
Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding ...
SANTA BARBARA, Calif.
Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets...
TEL AVIV, Israel & PARSIPPANY, N.J.
FDA warns of Adderall shortage after Teva manufacturing delay
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's warning of an Adderall shortage after Teva experiences a manufacturing delay.
The U.S. Food and Drug Administration said on Wednesday there was a shortage of Adderall, a treatment for attention deficit hyperactivity disorder, following intermittent manufacturing delays at Teva Ph...